Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
PLoS Genet ; 17(9): e1009777, 2021 09.
Article in English | MEDLINE | ID: mdl-34587162

ABSTRACT

Perturbation of the excitation/inhibition (E/I) balance leads to neurodevelopmental diseases including to autism spectrum disorders, intellectual disability, and epilepsy. Loss-of-function mutations in the DYRK1A gene, located on human chromosome 21 (Hsa21,) lead to an intellectual disability syndrome associated with microcephaly, epilepsy, and autistic troubles. Overexpression of DYRK1A, on the other hand, has been linked with learning and memory defects observed in people with Down syndrome (DS). Dyrk1a is expressed in both glutamatergic and GABAergic neurons, but its impact on each neuronal population has not yet been elucidated. Here we investigated the impact of Dyrk1a gene copy number variation in glutamatergic neurons using a conditional knockout allele of Dyrk1a crossed with the Tg(Camk2-Cre)4Gsc transgenic mouse. We explored this genetic modification in homozygotes, heterozygotes and combined with the Dp(16Lipi-Zbtb21)1Yey trisomic mouse model to unravel the consequence of Dyrk1a dosage from 0 to 3, to understand its role in normal physiology, and in MRD7 and DS. Overall, Dyrk1a dosage in postnatal glutamatergic neurons did not impact locomotor activity, working memory or epileptic susceptibility, but revealed that Dyrk1a is involved in long-term explicit memory. Molecular analyses pointed at a deregulation of transcriptional activity through immediate early genes and a role of DYRK1A at the glutamatergic post-synapse by deregulating and interacting with key post-synaptic proteins implicated in mechanism leading to long-term enhanced synaptic plasticity. Altogether, our work gives important information to understand the action of DYRK1A inhibitors and have a better therapeutic approach.


Subject(s)
Autistic Disorder/genetics , Cognition Disorders/genetics , Down Syndrome/genetics , Gene Dosage , Glutamic Acid/metabolism , Intellectual Disability/genetics , Neurons/metabolism , Speech Disorders/genetics , Animals , Brain/pathology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Cognition Disorders/complications , Disease Models, Animal , Down Syndrome/complications , Gene Expression Regulation , Humans , Mice , Mice, Transgenic , Proteomics/methods , Synaptic Transmission/genetics , Transcription, Genetic
2.
Mol Cell Neurosci ; 119: 103705, 2022 03.
Article in English | MEDLINE | ID: mdl-35158060

ABSTRACT

Down syndrome (DS) or Trisomy 21 is the most common genetic cause of mental retardation with severe learning and memory deficits. DS is due to the complete or partial triplication of human chromosome 21 (HSA21) triggering gene overexpression and protein synthesis alterations responsible for a plethora of mental and physical phenotypes. Among the diverse brain target systems that affect hippocampal-dependent learning and memory deficit impairments in DS, the upregulation of the endocannabinoid system (ECS), and notably the overexpression of the cannabinoid type-1 receptor (CB1), seems to play a major role. Combining various protein and gene expression targeted approaches using western blot, qRT-PCR and FISH techniques, we investigated the expression pattern of ECS components in the hippocampus (HPC) of male Ts65Dn mice. Among all the molecules that constitute the ECS, we found that the expression of the CB1 is altered in the HPC of Ts65Dn mice. CB1 distribution is differentially segregated between the dorsal and ventral part of the HPC and within the different cell populations that compose the HPC. CB1 expression is upregulated in GABAergic neurons of Ts65Dn mice whereas it is downregulated in glutamatergic neurons. These results highlight a complex regulation of the CB1 encoding gene (Cnr1) in Ts65Dn mice that could open new therapeutic solutions for this syndrome.


Subject(s)
Cannabinoids , Down Syndrome , Animals , Disease Models, Animal , Down Syndrome/genetics , Down Syndrome/metabolism , Hippocampus/metabolism , Male , Mice , Mice, Transgenic , Neurons/metabolism , Receptor, Cannabinoid, CB1/genetics , Receptor, Cannabinoid, CB1/metabolism
3.
Hum Mol Genet ; 24(23): 6736-55, 2015 Dec 01.
Article in English | MEDLINE | ID: mdl-26376863

ABSTRACT

ATP6AP2, an essential accessory component of the vacuolar H+ ATPase (V-ATPase), has been associated with intellectual disability (ID) and Parkinsonism. ATP6AP2 has been implicated in several signalling pathways; however, little is known regarding its role in the nervous system. To decipher its function in behaviour and cognition, we generated and characterized conditional knockdowns of ATP6AP2 in the nervous system of Drosophila and mouse models. In Drosophila, ATP6AP2 knockdown induced defective phototaxis and vacuolated photoreceptor neurons and pigment cells when depleted in eyes and altered short- and long-term memory when depleted in the mushroom body. In mouse, conditional Atp6ap2 deletion in glutamatergic neurons (Atp6ap2(Camk2aCre/0) mice) caused increased spontaneous locomotor activity and altered fear memory. Both Drosophila ATP6AP2 knockdown and Atp6ap2(Camk2aCre/0) mice presented with presynaptic transmission defects, and with an abnormal number and morphology of synapses. In addition, Atp6ap2(Camk2aCre/0) mice showed autophagy defects that led to axonal and neuronal degeneration in the cortex and hippocampus. Surprisingly, axon myelination was affected in our mutant mice, and axonal transport alterations were observed in Drosophila. In accordance with the identified phenotypes across species, genome-wide transcriptome profiling of Atp6ap2(Camk2aCre/0) mouse hippocampi revealed dysregulation of genes involved in myelination, action potential, membrane-bound vesicles and motor behaviour. In summary, ATP6AP2 disruption in mouse and fly leads to cognitive impairment and neurodegeneration, mimicking aspects of the neuropathology associated with ATP6AP2 mutations in humans. Our results identify ATP6AP2 as an essential gene for the nervous system.


Subject(s)
Cognition Disorders/etiology , Drosophila Proteins/genetics , Membrane Proteins/genetics , Nerve Degeneration/etiology , Proton-Translocating ATPases/genetics , Receptors, Cell Surface/genetics , Animals , Brain/metabolism , Brain/physiopathology , Cognition Disorders/genetics , Cognition Disorders/physiopathology , Disease Models, Animal , Drosophila , Female , Gene Knockdown Techniques , Intellectual Disability/genetics , Male , Mice , Nerve Degeneration/pathology , Neurons/metabolism , Neurons/physiology , Neurons/ultrastructure , Parkinsonian Disorders/genetics , Synapses/metabolism , Synapses/physiology , Synapses/ultrastructure
4.
Food Microbiol ; 40: 9-17, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24549192

ABSTRACT

The spoilage potential of isolates belonging to five bacterial groups/species (Shewanella baltica, Carnobacterium maltaromaticum, Aeromonas salmonicida, Vibrio sp., "other Gamma-Proteobacteria" [containing one strain of Pseudoalteromonas sp. and one strain of Psychrobacter sp.]) isolated from spoiled cooked and whole tropical shrimp stored under modified atmosphere packaging (MAP) was evaluated by inoculation into ionized cooked and peeled tropical shrimp followed by storage for 32 days at 8 °C. Microbial growth and sensory changes were monitored during the storage period. The major spoilage bacterial isolate groups were C. maltaromaticum and S. baltica. In order to characterize their spoilage potential further and to study the effect of their interactions, each of these two specific spoilage organisms (SSO) and one mixed-culture, C. maltaromaticum/S. baltica, were tested using a combination of complementary methods: molecular (PCR-TTGE), sensory, chemical, and conventional microbiological analyses. It was concluded that, in the mixed-culture-inoculated samples, both species groups imposed their spoilage characteristics.


Subject(s)
Bacteria/isolation & purification , Food Packaging/methods , Penaeidae/microbiology , Shellfish/microbiology , Animals , Bacteria/classification , Bacteria/genetics , Bacteria/growth & development , Cooking , Food Storage , Humans , Penaeidae/chemistry , Shellfish/analysis , Taste
5.
Eur J Pharmacol ; 921: 174870, 2022 Apr 15.
Article in English | MEDLINE | ID: mdl-35257716

ABSTRACT

BACKGROUND AND AIM: Metabolic syndrome (MetS) is a global health and economic burden. Finding a suitable pharmacological approach for managing this syndrome is crucial. We explored the therapeutic potential of mirabegron (MIR), a ß3-adrenergic receptor agonist, as a repurposed agent for the treatment of MetS and its cardiovascular consequences. METHODS: Thirty Watanabe heritable hyperlipidemic rabbits (WHHL) were divided into 3 groups: control, high-fructose high-fat diet (HFFD) and HFFD + MIR that received a chow diet, HFFD and HFFD along with MIR treatment, respectively. The protocol lasted for 12 weeks, during which weight and abdominal circumference were monitored; plasma fasting levels of lipids, glucose and insulin were measured and an intravenous glucose tolerance test (IVGTT) was performed. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Cardiac function was assessed using in-vivo and ex-vivo approaches. Vascular reactivity was estimated via isolated carotid arteries method. Aortic atherosclerosis was evaluated using histological and immuno-histochemical techniques. RESULTS: In contrast to the HFFD group, MIR-treated rabbits showed fasting insulin, HOMA-IR and TG levels stabilization and exhibited improved cardiac inotropy and lusitropy, while on the other hand, displayed aggravated atheroma plaque development. CONCLUSION: Long-term treatment with MIR prevented the increase in TG levels and the establishment of IR and enhanced the cardiac function of a rabbit animal model of MetS with combined dyslipidemia and IR.


Subject(s)
Atherosclerosis , Insulin Resistance , Acetanilides , Animals , Atherosclerosis/metabolism , Blood Glucose/metabolism , Diet, High-Fat/adverse effects , Fructose , Insulin , Insulin Resistance/physiology , Rabbits , Thiazoles
6.
Eur J Pharmacol ; 899: 173978, 2021 May 15.
Article in English | MEDLINE | ID: mdl-33691164

ABSTRACT

Metabolic syndrome is linked to an increased risk of cardiovascular complications by a mechanism involving mainly decreased nitric oxide (NO) bioavailability and impaired NO-soluble guanylate cyclase (sGC)- cyclic guanosine monophosphate (cGMP) signalling (NO-sGC-cGMP). To further develop this scientific point, this study aimed to investigate the effects of long-term treatment with BAY 41-2272 (a sGC stimulator) on cardiovascular reactivity of spontaneously hypertensive rats (SHR) as a model of metabolic syndrome. SHR were randomly divided into 3 groups: control group, cafeteria diet (CD)-fed group and CD-fed group treated daily with BAY 41-2272 (5 mg/kg) by gastric gavage for 12 weeks. In vivo measurements of body weight, abdominal circumference, blood pressure and glucose tolerance test were performed. At the end of the feeding period, ex vivo cumulative concentration-response curves were performed on isolated perfused heart (isoproterenol (0.1 nM - 1 µM)) and thoracic aorta (phenylephrine (1 nM-10 µM), acetylcholine (1 nM-10 µM), and sodium nitroprusside (SNP) (0.1 nM-0.1 µM)). We showed that chronic CD feeding induced abdominal obesity, hypertriglyceridemia, glucose intolerance and exacerbated arterial hypertension in SHR. Compared to control group, CD-fed group showed a decrease in ß-adrenoceptor-induced cardiac inotropy, in coronary perfusion pressure and in aortic contraction to phenylephrine. While relaxing effects of acetylcholine and SNP were unchanged. BAY 41-2272 long-term treatment markedly prevented arterial hypertension development and glucose intolerance, enhanced the α1-adrenoceptor-induced vasoconstriction, and restored cardiac inotropy and coronary vasodilation. These findings suggest that BAY 41-2272 may be a potential novel drug for preventing metabolic and cardiovascular complications of metabolic syndrome.


Subject(s)
Cardiovascular Diseases/prevention & control , Enzyme Activators/pharmacology , Metabolic Syndrome/prevention & control , Pyrazoles/pharmacology , Pyridines/pharmacology , Soluble Guanylyl Cyclase/metabolism , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/enzymology , Aorta, Thoracic/physiopathology , Cardiovascular Diseases/enzymology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/physiopathology , Coronary Circulation/drug effects , Cyclic GMP/metabolism , Disease Models, Animal , Enzyme Activation , Glucose Intolerance/enzymology , Glucose Intolerance/etiology , Glucose Intolerance/physiopathology , Glucose Intolerance/prevention & control , Hypertension/enzymology , Hypertension/etiology , Hypertension/physiopathology , Hypertension/prevention & control , Hypertriglyceridemia/enzymology , Hypertriglyceridemia/etiology , Hypertriglyceridemia/physiopathology , Hypertriglyceridemia/prevention & control , Isolated Heart Preparation , Male , Metabolic Syndrome/enzymology , Metabolic Syndrome/etiology , Metabolic Syndrome/physiopathology , Nitric Oxide Synthase Type II/metabolism , Obesity, Abdominal/enzymology , Obesity, Abdominal/etiology , Obesity, Abdominal/physiopathology , Obesity, Abdominal/prevention & control , Rats, Inbred SHR , Vasoconstriction/drug effects , Vasodilation/drug effects , Ventricular Function, Left/drug effects , Ventricular Pressure/drug effects
7.
PLoS One ; 14(11): e0223914, 2019.
Article in English | MEDLINE | ID: mdl-31697707

ABSTRACT

Much evidence indicates that metabolic syndrome is strongly correlated with a decrease in nitric oxide and an increase in oxidative stress leading to cardiovascular alterations. In recent years, gut microbiota has emerged as a new contributor to the metabolic syndrome establishment and associated cardiovascular diseases, but the underlying mechanisms remain unclear. We hypothesized that a positive modulation of cyclic guanosine monophosphate (cGMP) pathway, through phosphodiesterase type 5 (PDE5) inhibition could prevent cardiovascular alterations and gut dysbiosis that may be associated to metabolic syndrome. Spontaneously hypertensive rats (SHR) were randomly divided into 4 groups: control, cafeteria diet (CD) and sildenafil citrate treated groups (5mg/kg per os) were given either a CD or a standard chow diet for 10 weeks. Body weight, arterial blood pressure and glucose tolerance test were monitored. At the 10th week, cardiac inotropy and coronary perfusion pressure were evaluated on isolated heart according to Langendorff method. Cumulative concentration response curves to phenylephrine and acetylcholine were determined on thoracic aorta rings for vascular reactivity evaluation. Faecal samples were collected for the gut microbiota analysis. Compared to the control group, CD-fed rats showed a significant increase in body weight gain, arterial blood pressure and were glucose intolerant. This group showed also a decrease in ß-adrenoceptor-induced cardiac inotropy and coronary vasodilation. Gut microbiota analysis revealed a significant reduction in the abundance of Lactobocillus spp in cafeteria diet-fed rats when compared to the control ones. Sildenafil citrate long-term treatment decreased weight gain and arterial blood pressure, improved coronary vasodilation and reduced α1-adrenoceptor-induced vasoconstriction in CD group. However, it did not reverse gut dysbiosis induced by chronic CD feeding. These results suggest that cGMP pathway targeting may be a potential therapeutic strategy for the management of the metabolic syndrome and associated cardiovascular disorders.


Subject(s)
Cardiovascular Diseases/drug therapy , Metabolic Syndrome/drug therapy , Phosphodiesterase 5 Inhibitors/pharmacology , Sildenafil Citrate/pharmacology , Acetylcholine/metabolism , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Aorta, Thoracic/microbiology , Blood Pressure/drug effects , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/microbiology , Cyclic GMP/metabolism , Diet/methods , Disease Models, Animal , Gastrointestinal Microbiome/drug effects , Glucose Tolerance Test/methods , Male , Metabolic Syndrome/metabolism , Metabolic Syndrome/microbiology , Phenylephrine/metabolism , Rats , Rats, Inbred SHR , Vasodilation/drug effects , Vasodilator Agents/pharmacology
8.
Eur J Pharmacol ; 740: 66-71, 2014 Oct 05.
Article in English | MEDLINE | ID: mdl-25014758

ABSTRACT

This work was designed to investigate (i) the effect of superoxide dismutase (SOD) inhibition on endothelial function and (ii) the free radical-induced endothelial dysfunction in equine digital veins (EDVs) and equine digital arteries (EDAs) isolated from healthy horses. EDV and EDA rings were suspended in a 5 ml organ bath containing Krebs solution. After a 60 min equilibration period, EDV and EDA rings were contracted with phenylephrine. Then, cumulative concentration-response curves (CCRCs) to acetylcholine were performed. In both EDVs and EDAs, acetylcholine (1 nM to 10 µM) produced concentration-dependent relaxation. We investigated the influence of SOD inhibition by diethyldithiocarbamate (DETC; 100 µM), a CuZnSOD inhibitor, on EDAs and EDVs relaxant responses to acetylcholine. Acetylcholine -mediated relaxation was impaired by DETC only in EDVs. SOD activity assayed by a xanthine-xanthine oxidase method was higher in EDAs compared with EDVs (P<0.05). CCRCs to acetylcholine established in the presence of pyrogallol (30 µM) or homocysteine (20 µM), two superoxide anions generating systems showed that in both EDVs and EDAs, the acetylcholine-mediated relaxation was significantly impaired by pyrogallol and homocysteine. This impairment was more pronounced in EDVs than in EDAs. Moreover, the pyrogallol-induced impairment of acetylcholine-mediated relaxation was potentiated by DETC to a greater extent in EDVs. We concluded that due to the lower activity of SOD, EDVs are more sensitive to superoxide anions than EDAs. So, any alteration of superoxide anions metabolism is likely to have a more important impact on venous rather than arterial relaxation.


Subject(s)
Arteries/physiology , Superoxides/metabolism , Veins/physiology , Acetylcholine/pharmacology , Animals , Ditiocarb/pharmacology , Forelimb , Horses , In Vitro Techniques , Phenylephrine/pharmacology , Superoxides/antagonists & inhibitors , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects , Vasodilator Agents/pharmacology
9.
Int J Food Microbiol ; 160(3): 227-38, 2013 Jan 01.
Article in English | MEDLINE | ID: mdl-23290229

ABSTRACT

The spoilage potential of eight bacterial groups/species (Serratia spp., Hafnia alvei, Brochothrix thermosphacta, Carnobacterium maltaromaticum, Shewanella baltica, Lactococcus piscium, Photobacterium phosphoreum, "other Enterobacteriaceae" [containing one strain of Moellerella sp., Morganella sp. and Pectobacterium sp.]) isolated from spoiled raw salmon fillets stored under modified atmosphere packaging (MAP) was evaluated by inoculation into sterile raw salmon cubes followed by storage for 12days at 8°C. Microbial growth and sensory changes were monitored during the storage period. The dominant spoilage bacteria were C. maltaromaticum, H. alvei and P. phosphoreum. In order to further characterize their spoilage potential and to study the effect of their interactions, each of these 3 specific spoilage organisms (SSO) and two mixed-cultures, C. maltaromaticum/H. alvei and C. maltaromaticum/P. phosphoreum were tested in the sterile salmon model system using a combination of complementary methods: molecular (PCR-TTGE), sensory, chemical and conventional microbiological analyses. It was concluded that, in the mixed-culture inoculated samples, the dominant species determined the spoilage characteristics. The volatile fraction of P. phosphoreum inoculated samples was analyzed by solid-phase microextraction (SPME) followed by gas chromatography coupled to mass spectrometry (GC-MS). Among the specific volatile compounds present on P. phosphoreum spoiled inoculated samples, acetic acid was correlated with sensory analysis and can be proposed as a raw salmon spoilage marker.


Subject(s)
Bacterial Physiological Phenomena , Food Microbiology , Meat/microbiology , Salmo salar , Animals , Bacteria/growth & development , Bacteria/isolation & purification , Bacterial Load , Food Packaging/standards , Humans , Meat/analysis , Odorants/analysis , Sensation , Time Factors , Volatile Organic Compounds/analysis
10.
Int J Food Microbiol ; 147(3): 195-202, 2011 Jun 30.
Article in English | MEDLINE | ID: mdl-21531471

ABSTRACT

The spoilage potential of six bacterial species isolated from cooked and peeled tropical shrimps (Brochothrix thermosphacta, Serratia liquefaciens-like, Carnobacterium maltaromaticum, Carnobacterium divergens, Carnobacterium alterfunditum-like and Vagococcus penaei sp. nov.) was evaluated. The bacteria were inoculated into shrimps, packaged in a modified atmosphere and stored for 27 days at 8 °C. Twice a week, microbial growth, as well as chemical and sensory changes, were monitored during the storage period. The bacteria mainly involved in shrimp spoilage were B. thermosphacta, S. liquefaciens-like and C. maltaromaticum whose main characteristic odours were cheese-sour, cabbage-amine and cheese-sour-butter, respectively. The volatile fraction of the inoculated shrimp samples was analysed by solid-phase microextraction (SPME) and gas chromatography coupled to mass spectrometry (GC-MS). This method showed that the characteristic odours were most likely induced by the production of volatile compounds such as 3-methyl-1-butanal, 2,3-butanedione, 2-methyl-1-butanal, 2,3-heptanedione and trimethylamine.


Subject(s)
Bacteria/growth & development , Decapoda/microbiology , Food Microbiology , Shellfish/microbiology , Volatile Organic Compounds/analysis , Air Pollutants/analysis , Air Pollutants/chemistry , Animals , Bacteria/isolation & purification , Brochothrix/growth & development , Brochothrix/isolation & purification , Carnobacterium/growth & development , Carnobacterium/isolation & purification , Gas Chromatography-Mass Spectrometry , Hydrogen-Ion Concentration , Odorants/analysis , Serratia liquefaciens/growth & development , Serratia liquefaciens/isolation & purification , Solid Phase Microextraction , Volatile Organic Compounds/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL